2023-01-24 10:56:00

2022 Novo Holdings Seed Investments team Review/Business Update

Logo PR Newswire
PR Newswire
  • Two successful exits – Syndesi and BioPhero
  • Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and MinervaX)
  • Led three new seed investments and incubating additional projects
  • Expanded team as part of strong investment in global talent to access innovation
  • REPAIR Impact Fund making strides in the vital combat against Antimicrobial Resistance

COPENHAGEN, Denmark, Jan. 24, 2023 /PRNewswire/ -- Seed Investments, the early stage investment and company creation team of Novo Holdings, today publishes its review of 2022 – delivering results in a challenging market.

The Seed Investments team is committed to identifying, building and guiding the most transformative healthcare ventures throughout their life cycle. 2022 saw the team deliver strong results despite market headwinds. For more information, please visit link on the website.

Commenting on another highly successful year, Søren Møller, Managing Partner at Novo Seeds, said: "We are in a golden era of innovation. We remain dedicated to company creation and early stage investment as we continue to see an increasing number of exciting investment opportunities, and we do not see it slowing down. We have had a very successful year, with two portfolio M&As, large financings and three new investments."

"As one of the leading life sciences early stage VCs in Europe, we proactively identify global breakthrough scientific discoveries that have the potential to deliver innovative therapies for patients. Working with our network of highly experienced Entrepreneurs-in-Residence and Founders to setup ambitious biotech startups. In 2022, we accelerated our company building with an expert run lab that de-risks and validates discoveries before they are assembled into biotech start-ups."

About Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.

Cision View original content:https://www.prnewswire.co.uk/news-releases/2022-novo-holdings-seed-investments-team-reviewbusiness-update-301729086.html

Logo The Business Journals
Technology2023-01-23 19:47:07
Genetesis has added three new executives to its team as it nears a key FDA approval.

Logo GlobeNewswire
SciencePress Release2023-01-23 14:22:00
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis ), a multi-asset rare and...

Logo EIN Presswire
HealthPress Release2023-01-23 13:38:17
Emergen Research Logo Increasing number of drug relapse and drug resistance cases and application of QSP in drug development processes are some key factors...

Logo EIN Presswire
Emergen Research Logo Limited entry barriers resulting in the entry of players of different tiers is a key factor driving biostimulants market revenue growth...

Logo PR Newswire
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at...

Logo Nasdaq
Business / FinanceBy Mt Newswires2023-01-23 21:00:54
Healthcare stocks were hanging on for slim gains Monday, with the NYSE Health Care Index rising 0.1% and the Health Care Select Sector SPDR Fund (XLV) up...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-24 06:30:00
Attachment EN_H1 2023 conferences_PR_20230124_F 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Posted In: News Press...

Logo GlobeNewswire
SciencePress Release2023-01-23 13:00:00
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023 Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory...

Logo PR Newswire
TechnologyPress Release2023-01-23 12:28:00
BOCA RATON, Fla., Jan. 23, 2023 /PRNewswire/ -- PreIPO ®, a leading provider of innovative financial technology solutions, announced today a strategic...

Logo GlobeNewswire
SciencePress Release2023-01-24 06:15:00
Successful implementation of strategic decision to focus on anti-infectives and stronger than expected revenue lead to profitability earlier than anticipated...

Logo GlobeNewswire
SciencePress Release2023-01-24 06:30:00
Press Release Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023 January 24, 2023 release at 7:30 am CET Sophia...

Logo EIN Presswire
HealthPress Release2023-01-23 11:44:17
Emergen Research Logo According to Emergen Research the market is expected to grow USD 38.79 billion by 2027, exhibiting a CAGR of 10.2% during the forecast...

Logo NewsFileCorp
Press Release2023-01-23 14:37:00
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to...

Logo GlobeNewswire
SciencePress Release2023-01-23 11:00:00
VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 02:00:00
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Bioventus...

Logo GlobeNewswire
SciencePress Release2023-01-24 09:00:00
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab...

Logo GlobeNewswire
SciencePress Release2023-01-23 18:25:00
Announced Earlier Today -Notice Received from ANDA Filer for FIRDAPSE CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc....

Logo GlobeNewswire
SciencePress Release2023-01-23 21:30:00
Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022 LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems,...

Logo GlobeNewswire
SciencePress Release2023-01-24 08:00:00
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and...